Regular ArticleSex-specific risk factors for recurrent venous thromboembolism
Introduction
Venous thromboembolism (VTE) is a chronic, multifactorial and potentially fatal disease affecting more than 1 person for 1000 per year [1], [2]. The risk of recurrence is high in the first 2 years after stopping anticoagulation therapy with a cumulative incidence of recurrent VTE of 25% after 5 years [3]. Prolonged anticoagulation treatment can prevent most episodes of recurrence but this must be balanced with the risk of bleeding in particular in persons at low risk of recurrence [4]. Stratification of patients in low or high risk groups appears essential to tailor the duration of the anticoagulation therapy to each patient [3], [5]. Many risk factors for recurrent VTE have been identified [6] and several studies showed that men have about 50% higher risk of recurrent VTE than women after anticoagulation therapy is stopped [7]. This sex difference in the risk of recurrent VTE was so far largely unexplained and different hypothesis have been made. Hormonal exposure of women at the time of their first event has been suggested to partly explain the lower recurrence risk observed in women compared to men [8], [9]. However, some studies showed that the difference in the recurrence risk according to gender persisted after exclusion of women with hormonal factors at first event [10], [11]. Recently, younger age at first event in women has also been considered to explain the difference in the recurrence risk between men and women [9], [12]. By contrast, some studies found that age did not play any role in the VTE recurrence risk neither in men nor in women [13], [14].
All hypotheses that have been proposed to explain the discrepancy between men and women on the risk of recurrent are still under debate. Identification of sex-specific risk factors for recurrent VTE could provide new insight into the understanding of sex-related risk of recurrent VTE.
In this context we set up a prospective cohort study aimed to assess potential sex-specific risk factors for recurrent VTE.
Section snippets
Population and study design
The FARIVE study is a case–control study associated with a pre-specified cohort study of all idiopathic cases performed in 11 centers in France. The detailed methodology of the case–control study has been previously described [15]. The present work is based on the FARIVE cohort study. Since January 2003, all consecutive patients treated as inpatients or outpatients for a first episode of idiopathic proximal Deep Vein Thrombosis (DVT) and/or Pulmonary Embolism (PE) who fulfilled all inclusion
Results
Between 2003 and 2009, 990 patients were included in the cohort (Fig. 1). Of these, 407 patients were excluded because of the following conditions: 9 removed their consent to the study, 71 were lost for follow-up, 208 patients did not stop the anticoagulation therapy, no information about the date of discontinuing anticoagulation for 6 patients, 113 had surgery, trauma or pregnancy within the 3 months preceding first event or developed a cancer during the follow-up. A total of 583 patients (234
Discussion
This large prospective cohort study including 583 patients with a first episode of VTE showed that male sex was associated with a higher risk of recurrent VTE. However, this sex-related difference in VTE recurrence risk did not persist after 50 years. This result may be partly explained by the increased risk of recurrent VTE among older women compared with younger men. Recent studies confirmed that older age was associated with an increasing risk of recurrent VTE in women but not in men [5], [9]
Conflicts of interest statement
None to declare.
Acknowledgment
Joseph Emmerich had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Financial support
The FARIVE study was supported by Fondation pour la Recherche Médicale, Programme Hospitalier de recherche clinique (PHRC), Fondation de France, and the Leducq Foundation (LINAT Leducq International Network Against Thrombosis).
References (19)
- et al.
Incidence and mortality of venous thrombosis: a population-based study
J Thromb Haemost
(Apr 2007) Duration of anticoagulant therapy for patients with venous thromboembolism
Thromb Res
(2008)- et al.
Unprovoked venous thromboembolism: Short term or indefinite anticoagulation? Balancing long-term risk and benefit
Blood Rev
(Jul-Sep 2010) - et al.
Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis
Lancet
(Jul 29 2006) - et al.
Hormonal factors and risk of recurrent venous thrombosis: the prevention of recurrent venous thromboembolism trial
J Thromb Haemost
(Oct 2006) - et al.
Sex, age and normal post-anticoagulation d-dimer as risk factors for recurrence after idiopathic venous thromboembolism in the prolong study extension
J Thromb Haemost
(Jun 15 2010) - et al.
High risk of recurrent venous thromboembolism in men
J Thromb Haemost
(Dec 2004) - et al.
A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in thrombophilic families
Blood
(Sep 3 2009) - et al.
Sex difference in risk of recurrent venous thrombosis and the risk profile for a second event
J Thromb Haemost
(Aug 3 2010)
Cited by (34)
Sex-specific differences in the presentation, clinical course, and quality of life of patients with acute venous thromboembolism according to baseline risk factors. Insights from the PREFER in VTE
2021, European Journal of Internal MedicineCitation Excerpt :Studies that do not include patients with first VTE only seem to find less often sex differences in recurrence rates[4]. Older patient populations, such as ours, may display less often sex differences in recurrence rates than younger ones, in line with the finding that male prominence in VTE recurrence rates attenuates considerably in patients older than 50 [40] or even 40 [41] years. With regard to the risk for recurrence imposed by different provoking risk factors for VTE, our results are consistent with those of a recent national cohort study of 73,993 patients with VTE, which reported a similar 6-month risk of recurrence in patients with unprovoked and provoked VTE and also observed a particularly high risk of recurrence in women with cancer [42].
Long-term recurrence risk after a first venous thromboembolism in men and women under 50 years old: A French prospective cohort
2021, European Journal of Internal MedicineCitation Excerpt :Such risk-benefit assessment is difficult in patients under 50 years old because, in this low bleeding risk population, data on the risk factors of recurrent VTE are conflicting and pathophysiology is uncertain. Several studies pointed out a higher risk of VTE recurrence after anticoagulant discontinuation in men, either under 50 [8–10] or older [11–19]. In these studies, the difference of recurrence risk between men and women was maintained [9,11,15,17-19] or not [8,10,14] after exclusion of women with a first hormone-related episode.
Diagnostic and therapeutic management of venous thromboembolic disease in obese patients
2020, Revue des Maladies RespiratoiresWomen, thrombosis, and cancer
2019, Thrombosis ResearchOSA Is a Risk Factor for Recurrent VTE
2016, ChestCitation Excerpt :Eichinger et al12 showed that compared with patients of normal weight, the risk of recurrence was 60% higher among obese patients.12 Other groups have also reported that obesity is a risk factor for recurrent VTE in prospective studies,10,14,39 and an algorithm developed to predict recurrent venous thromboembolism includes obesity.40 To our knowledge, the potential impact of OSA as a risk factor for PE recurrence has never been explored.
Recurrence risk of idiopathic venous thromboembolism
2016, Revista Clinica Espanola